Songül Yılmaz1,2, Z Birsin Özçakar3, Aysel Taktak4, Saba Kiremitçi5, Arzu Ensari5, Handan Dinçaslan6, Fatoş Yalçınkaya3. 1. Department of Pediatrics, Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey. songulyilmaz23@gmail.com. 2. Çocuk Sağlığı ve Hastalıkları AD, Çocuk Nefroloji Ünitesi, Ankara Üniversitesi Tıp Fakültesi, Dikimevi, Ankara, Turkey. songulyilmaz23@gmail.com. 3. Department of Pediatrics, Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey. 4. Department of Pediatric Nephrology, Ankara Child Health Hematology and Oncology Education Research Hospital, Ankara, Turkey. 5. Department of Pathology, Ankara University School of Medicine, Ankara, Turkey. 6. Department of Pediatrics, Division of Pediatric Oncology, Ankara University School of Medicine, Ankara, Turkey.
Abstract
BACKGROUND: Targeting the vascular endothelial growth factor (VEGF) signaling pathway has become an important approach to current cancer therapy. Anti-VEGF therapy-related renal adverse effects may present as hypertension, non-nephrotic proteinuria, and rarely as nephrotic syndrome (NS) and acute kidney injury. CASE-DIAGNOSIS/TREATMENT: In this report, we present a 15-year-old boy who had developed nephrotic syndrome and thrombotic microangiopathy 26 months after administration of anti-VEGF therapy. Treatment was discontinued and nephrotic syndrome remitted spontaneously within 3 months. CONCLUSIONS: Nephrologists should be aware of the side effects of anti-VEGF therapy. Early diagnosis and prompt management with withdrawal of the agents will result in spontaneous remission.
BACKGROUND: Targeting the vascular endothelial growth factor (VEGF) signaling pathway has become an important approach to current cancer therapy. Anti-VEGF therapy-related renal adverse effects may present as hypertension, non-nephrotic proteinuria, and rarely as nephrotic syndrome (NS) and acute kidney injury. CASE-DIAGNOSIS/TREATMENT: In this report, we present a 15-year-old boy who had developed nephrotic syndrome and thrombotic microangiopathy 26 months after administration of anti-VEGF therapy. Treatment was discontinued and nephrotic syndrome remitted spontaneously within 3 months. CONCLUSIONS: Nephrologists should be aware of the side effects of anti-VEGF therapy. Early diagnosis and prompt management with withdrawal of the agents will result in spontaneous remission.
Authors: Scott M Wilhelm; Lila Adnane; Philippa Newell; Augusto Villanueva; Josep M Llovet; Mark Lynch Journal: Mol Cancer Ther Date: 2008-10 Impact factor: 6.261
Authors: James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi Journal: Cancer Date: 2013-09-19 Impact factor: 6.860
Authors: Nilofer S Azad; Edwin M Posadas; Virginia E Kwitkowski; Seth M Steinberg; Lokesh Jain; Christina M Annunziata; Lori Minasian; Gisele Sarosy; Herbert L Kotz; Ahalya Premkumar; Liang Cao; Deborah McNally; Catherine Chow; Helen X Chen; John J Wright; William D Figg; Elise C Kohn Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 50.717